Once-daily ORACEA® Capsules are a unique formulation of doxycycline1

Early and sustained efficacy to treat the inflammation associated with rosacea demonstrated in clinical studies1

Treatment without an antimicrobial effect may be beneficial to patients.1

treatment without an antimicrobial effect

Rosacea is a chronic, inflammatory condition with no bacterial pathogenesis

The effective formulation of ORACEA 30 mg immediate release and 10 mg delayed-release beads provides:

  • Comparable efficacy to doxycycline 100 mg (an antibiotic dose)2
  • No evidence of antimicrobial activity1
  • No evidence of bacterial resistance in a 9-month study1

ORACEA Capsules are formulated for an effective anti-inflammatory response1

  • ORACEA Capsules help break the cycle of inflammation associated with rosacea, reducing papules and pustules without inducing bacterial resistance1
  • In a clinical study, results were seen as early as week 3 and continued through week 161
ORACEA CAPSULES ARE THE #1 ROSACEA BRAND AMONG DERMATOLOGISTS

Visible Results

ORACEA Capsules are formulated for an effective anti-inflammatory response

Learn More

ORACEA Capsules Tolerability

Read about the favorable tolerability profile of ORACEA Capsules

Learn More

Patient Savings

Learn how your patients can save on prescriptions for ORACEA Capsules

Learn More
References:
  1. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56(5):791-802.
  2. Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol. 2008;7(6):573-576.
  3. Data on file, Galderma Laboratories, L.P.

Important Safety Information

Indication: ORACEA® (doxycycline, USP) 40 mg* Capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA Capsules do not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA Capsules were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. Warnings/Precautions: ORACEA Capsules should not be used to treat or prevent infections. ORACEA Capsules should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA Capsules should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials, ORACEA Capsules patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA Capsules treatment beyond 16 weeks and safety beyond 9 months have not been established.

*30 mg immediate release & 10 mg delayed release beads

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

To get your Patient Savings Card, click OK below. You will be redirected to an external website that is independently operated and not managed by Galderma Laboratories, L.P. Galderma assumes no responsibility for the site you are about to visit. If you do not wish to leave Oracea.com, click CANCEL. Otherwise, click OK to continue.

Oracea Logo

Important Safety Information

Indication: ORACEA® (doxycycline, USP) 40 mg* Capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA Capsules do not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA Capsules were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. Warnings/Precautions: ORACEA Capsules should not be used to treat or prevent infections. ORACEA Capsules should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA Capsules should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials, ORACEA Capsules patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA Capsules treatment beyond 16 weeks and safety beyond 9 months have not been established.

*30 mg immediate release & 10 mg delayed release beads